Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.5352W HIGH $46.50
Volume
574.16 K
Value Traded
282.56 K
Short % Float
5.78%
Days to Cover
1.4
-15.45%Week
-50.69%1 Month
-61.18%3 Month
-66.42%6 Month
-98.13%5 Year
-97.18%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.79 M
EPS (TTM)
-6.74
P/E Ratio
-
Ent. Value
171.24 K
Total Shares
6.98 M
Float Shares
7.25 M
Insiders
2.61%
Institutions
8.00%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CODX Catalyst Timeline
Dated clinical, regulatory and corporate events for Co-Diagnostics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Co-Diagnostics, Inc.
396Total events
14Upcoming
63Tier-1 (high impact)
2019 to 2026Coverage
Upcoming catalysts 2
Event history 50
●Trial InitiationTrial
Analytical studies initiated for SARAGENE Bundibugyo Virus Test at third-party lab
Ebola virus disease (Bundibugyo species)source ↗
▲Preclinical PoCPreclinical
Proof-of-concept completed for extraction-free Co-Primers Ebola test on Co-Dx PCR Pro
Ebola virus diseasesource ↗
▲Manufacturing MilestoneCMC / Inspection
CoSara sent 200 Bundibugyo test kits to third-party lab for analytical studies
Ebola (Bundibugyo virus)source ↗
●Development Candidate NominationPreclinical
CoSara actively developing second-generation pan-Ebola assay
Ebola virus disease (pan-Ebola)source ↗
▲Trial InitiationTrial
CoSara initiates clinical studies for TB test on PCR Pro instrument in India
tuberculosissource ↗
●Enrollment UpdateTrial
PCR Pro instruments and MTB test kits deployed to select labs across India for TB testing evaluation
tuberculosissource ↗
▲Enrollment UpdateTrial
PCR Pro instruments and MTB test kits deployed to select labs across India
tuberculosissource ↗
▲Other Regulator MilestoneEx-US Regulatory
Invited to participate in UNOPS Global Implementation Workshop on NPOC TB Diagnostics in Bangkok
tuberculosissource ↗
▲Enrollment CompleteTrial
Completed clinical study enrolling >1,400 patients across 9 sites
upper respiratory infectionsource ↗
●Timing GuidancePresentation
Targeted 510(k) and CLIA Waiver by Application submission to FDA
upper respiratory infectionsource ↗
▲Manufacturing MilestoneCMC / Inspection
Completed analytical performance studies (27 studies, >10,000 PCR test cup runs)
upper respiratory infectionsource ↗
▲Partnership / LicenseCorporate
CoMira delegation visits Co-Diagnostics headquarters for technology transfer planning
▲Manufacturing MilestoneCMC / Inspection
Unveiling of future automated manufacturing line for CoMira technology transfer
▲Partnership / LicenseCorporate
Exclusive distribution agreement for Co-Dx PCR platform in Mexico
▲Preclinical PoCPreclinical
Continued progress in Ebola PCR development program with CoSara
Ebolasource ↗
▲Other Regulator MilestoneEx-US Regulatory
Advanced PCR assay development strategy for BDBV with CoSara JV
Ebola disease (Bundibugyo virus)source ↗
▼Equity OfferingCorporate
Private placement of common stock and warrants for $3.0 million gross proceeds
▲Platform ValidationPreclinical
Completed assay development strategy for BDBV
Ebola (Bundibugyo virus)source ↗
●Other Regulator MilestoneEx-US Regulatory
WHO declared Ebola outbreak a Public Health Emergency of International Concern
Ebola disease (Bundibugyo virus)source ↗
▲Other Regulator MilestoneEx-US Regulatory
CoMira finalizes lease agreement for manufacturing facility in Sudair Industrial City, Saudi Arabia
◆Oral PresentationPresentation
Presentation of Co-Dx MTB test at Stop TB Partnership Summit roundtable
tuberculosissource ↗
●Other Regulator MilestoneEx-US Regulatory
Executives to participate in WTC Utah trade mission in Switzerland and Germany
▲Other Regulator MilestoneEx-US Regulatory
CoMira receives MODON approval for land allocation in Sudair Industrial City
◆Trial InitiationTrial
Expected commencement of clinical performance studies in India
tuberculosissource ↗
▲Other Regulator MilestoneEx-US Regulatory
Shipped PCR Pro instruments, Co-Dx PCR MTB test kits, and sample prep instruments to India for clinical studies
tuberculosissource ↗
▲Other Regulator MilestoneEx-US Regulatory
PCR Pro instrument received CDSCO license to be manufactured and sold as medical device in India
▲Partnership / LicenseCorporate
CoSara expands commercial territory to Bangladesh, Pakistan, Nepal, Sri Lanka
◆Oral PresentationPresentation
Presentation at Medical Korea 2026 highlighting Co-Dx PCR point-of-care platform
▲Patent GrantedIP / Competition
Japan Patent Office granted patent covering Co-Dx PCR platform technologies
◆Oral PresentationPresentation
Co-Diagnostics to showcase PCR platform at World Health Expo Labs Dubai
▲Partnership / LicenseCorporate
Formation of CoMira Diagnostics joint venture with Arabian Eagle Manufacturing
▲Other Regulator MilestoneEx-US Regulatory
CDSCO license on Form MD-5 to manufacture CoSara PCR Pro instrument
▲Manufacturing MilestoneCMC / Inspection
CoSara receives ISO 13485:2016 certification for manufacturing facility in Vadodara, India
●Other Regulator MilestoneEx-US Regulatory
CoSara exhibited at 13th ACLAP conference in Maharashtra
▼Reverse Stock SplitCorporate
Reverse stock split at 1-for-30 ratio effective January 2, 2026
▲Other Regulator MilestoneEx-US Regulatory
Received CDSCO license to manufacture and sell CoSara PCR Pro instrument in India
▲Manufacturing MilestoneCoSaraCMC / Inspection
Received ISO 13485 certification for CoSara's manufacturing facility in India
▲Partnership / LicenseCorporate
Expanded CoSara Diagnostics' commercial and distribution territory across South Asia to include Bangladesh, Pakistan, Nepal, and Sri Lanka
▲Trial InitiationTrial
Initiated shipments of PCR Pro instruments and TB test materials to India to support upcoming clinical performance studies
tuberculosissource ↗
▲Enrollment CompleteTrial
Completed enrollment in upper respiratory Co-Dx test clinical studies with more than 1,400 patients
upper respiratorysource ↗
▲Manufacturing MilestoneCoMiraCMC / Inspection
Advanced CoMira Diagnostics' manufacturing facility in Sudair Industrial City, KSA through regulatory approval and lease execution
▲Preclinical PoCPreclinical
In silico analysis confirms Logix Smart ABC test reactivity against influenza A H3N2 subclade K
influenza A, influenza B, COVID-19source ↗
▲Platform ValidationPreclinical
In silico analysis confirms Logix Smart ABC test reactivity against Flu A H3N2 subclade K
Influenza A, Influenza B, COVID-19source ↗
●Oral PresentationPresentation
Presentation at Point-of-Care Testing 2025 Exhibition and Conference
Past FDA Catalysts and PDUFA Decisions
How CODX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Co-Diagnostics, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every CODX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Egan Dwight HDirector, Officer (Chief Executive Officer) | Grant/Award | 4,584 29,526 held | $0.00 | 05/23/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CODX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CODX for Q2 2026. | ||||
CODX Institutional Ownership Trends
CODX Short Interest
Shares sold short, counted twice a month.
5.78%
Short % of Float
of tradable shares sold short
656.4K
Shares Sold Short
+56.7% vs prior count
1.4 Low
Days to Cover
trading days of normal volume to buy every short share back
464.4K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CODX ranks across every disease it competes in
Competitive Position is a premium feature
See how CODX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCODX News
CODX▼ -0.2%today
Co-Diagnostics' Joint Venture CoSara Diagnostics Completes Clinical Study and Regulatory Submission for Point-of-Care Tuberculosis Test, Sets Stage for Commercial Launch in India
Co-Diagnostics' joint venture, CoSara Diagnostics, has completed a clinical study for its PCR tuberculosis test, achieving 97.3% sensitivity and 96.0% specificity. The test has been submitted for regulatory clearance to India's CDSCO, with commercial launch anticipated before the end of 2026. The infrastructure for testing is already established in India.
Read more →CODXCo-Diagnostics' Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
Co-Diagnostics' joint venture CoMira Diagnostics received an invitation from the Saudi Ministry of Industry to attend the NUWATIN 2026 Forum. The company plans to use this event to advance technology transfer and local manufacturing initiatives under Saudi Vision 2030. This strategic engagement follows the recent execution of a lease for a new manufacturing facility in Sudair Industrial City.
Read more →CODX▼ -6.5%on this newsshared move
Co-Diagnostics Highlights PCR Platform Capabilities for Potential Plague Detection
Co-Diagnostics highlighted the capabilities of its Co-Dx PCR Pro platform for potential plague diagnostics following a recent death linked to possible pneumonic plague. The company emphasized its experience with rapid-response diagnostics during past outbreaks and its ongoing investments in technology and infrastructure. While no specific plague test is in development, Co-Diagnostics is monitoring the situation closely.
Read more →CODXCo-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe
Co-Diagnostics has announced its first full Vector Smart laboratory installation for the Ute Indian Tribe Mosquito Abatement Department. This installation will allow the Tribe to conduct in-house PCR testing for mosquito pools, enhancing their mosquito surveillance capabilities. The initiative aligns with federal efforts to improve detection of mosquito-borne diseases and supports the Tribe's self-determination in managing public health.
Read more →CODXCo-Diagnostics Highlights Vector Smart® Momentum Following New Federal Initiative on Vector-Borne Disease
Co-Diagnostics, Inc. is highlighting the momentum of its Vector Smart mosquito surveillance business following a new federal initiative aimed at combating vector-borne diseases. The Executive Order directs the Department of Health and Human Services to pursue rapid diagnostics and emphasizes the use of advanced technologies. Co-Dx plans to participate in several upcoming conferences to engage with stakeholders relevant to this initiative.
Read more →CODXCo-Diagnostics to Showcase Co-Dx PCR Platform* and MTB Test at WHX Labs Johannesburg, Highlight Ebola Assay Development
Co-Diagnostics, Inc. is participating in WHX Labs Johannesburg to showcase its Co-Dx PCR platform and MTB test. The company is developing an Ebola assay to enhance decentralized testing capabilities amid a significant outbreak in the Democratic Republic of the Congo. Additionally, the Co-Dx PCR MTB test aims to address the high burden of tuberculosis in Africa. The participation is supported by a State Trade Expansion Program grant.
Read more →CODXCo-Diagnostics to Participate in Global Health Events During UN General Assembly Week
Co-Diagnostics, Inc. will participate in two global health events during the UN General Assembly week, focusing on tuberculosis and pandemic preparedness. The company's Chief Commercialization Officer will represent Co-Dx at these events, highlighting its advancements in molecular diagnostics. Ongoing clinical studies for its tuberculosis test and a recent FDA submission for a respiratory multiplex test are also noted.
Read more →CODX▲ +6.8%on this news· ran to +22% by day 3
Co-Diagnostics to Participate in Global Health Roundtable on Ebola and Outbreak Innovation
Co-Diagnostics, Inc. will participate in a roundtable on Ebola response in New York City, focusing on technologies for outbreak management. The discussion includes U.S. health officials and global health leaders. Co-Dx is advancing its Bundibugyo virus tests and collaborating with ReadyGo Diagnostics to enhance decentralized Ebola detection. However, their PCR platform is still under regulatory review.
Read more →CODXCo-Diagnostics to Participate in Joint WHO/Unitaid/UNAIDS Annual Consultation Meeting on September 17-18, 2026
Co-Diagnostics, Inc. will participate in the WHO/Unitaid/UNAIDS Annual Consultation Meeting on September 17-18, 2026, in Geneva. Joseph Featherstone, the Executive VP of Business Development, will represent the company. This meeting aims to enhance equitable access to diagnostics. Co-Dx's PCR MTB test is under clinical performance studies in India.
Read more →CODX▼ -17.5%on this newsshared move
Co-Diagnostics and ReadyGo Collaborate to Evaluate Blood-Based Molecular Testing at the Point of Need, Starting with Ebola
Co-Diagnostics and ReadyGo are collaborating to evaluate blood-based molecular testing for Ebola detection using the Co-Dx PCR platform. This partnership aims to enhance testing accessibility in decentralized settings, potentially expanding to other bloodborne pathogens like HIV and hepatitis B and C. The companies are currently assessing the compatibility of their technologies, with no guarantees of commercial viability.
Read more →CODX▼ -17.5%on this newsshared move
Co-Diagnostics to Hold Press Conference
Co-Diagnostics, Inc. will hold a press conference on September 16, 2026, at 10:30 a.m. ET, inviting media, analysts, and investors to attend in person or via live webcast. CEO Dwight Egan will present and participate in a Q&A session. The event highlights the company's advancements in molecular diagnostics.
Read more →CODXCo-Diagnostics Completes New Vector Smart® Laboratory Installations Amid Rising Dengue Activity in Florida
Co-Diagnostics has completed installations of two Vector Smart laboratories in Florida and is training staff in Indiana. This expansion comes amid rising dengue cases in the state, with 73 locally acquired cases reported. The Vector Smart platform aims to enhance public health decision-making by providing rapid PCR data for mosquito-borne diseases.
Read more →CODXCo-Diagnostics Launches Integrated Cloud and Mobile Infrastructure in India
Co-Diagnostics, Inc. has launched an integrated cloud infrastructure in India to support ongoing clinical studies for its tuberculosis test. This infrastructure allows for secure data management and mobile-based test analysis, enhancing decentralized testing capabilities. The initiative is partly funded by the Gates Foundation and aims to replicate the model in other markets. However, the Co-Dx PCR platform is still subject to FDA review and not available for sale.
Read more →CODX▼ -6.3%on this newsshared move
Co-Diagnostics Expands Vector Smart® Customer Reach with First International Installation in USAF Base
Co-Diagnostics, Inc. has announced the first international deployment of its Vector Smart mosquito surveillance platform at a USAF base. This expansion follows significant domestic growth and aims to meet the demand for rapid mosquito surveillance. The platform includes multiplex PCR assays designed to detect various mosquito-borne pathogens, contributing to public health efforts.
Read more →CODXCo-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event
Co-Diagnostics, Inc. participated in the Salt Lake Business Journal's Medical Devices and Innovation Roundtable, discussing industry innovations and challenges. The company is advancing its Co-Dx PCR Flu A/B & RSV test towards FDA submission, while preparing for potential commercialization. However, the platform is still pending regulatory clearance.
Read more →CODX▼ -6%on this news· ran to -26% by day 3shared move
Co-Diagnostics Reports Second Quarter 2026 Financial Results
Co-Diagnostics, Inc. reported its second quarter 2026 financial results, highlighting significant operational progress and advancements in regulatory submissions. The company successfully submitted an FDA 510(k) application for its Co-Dx PCR Flu A/B & RSV test and expanded its manufacturing strategy in Saudi Arabia. Despite a net loss of $6.3 million, revenue increased slightly from the previous year, indicating growth potential.
Read more →CODX▼ -5.3%on this news
Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test
Co-Diagnostics has submitted a Dual 510(k) premarket notification and a CLIA Waiver application to the FDA for its Co-Dx PCR Flu A/B & RSV test. This submission marks a significant milestone for the company, aiming to enhance decentralized PCR diagnostics. The submission is backed by extensive clinical and analytical studies involving over 1,400 patients. If approved, the test could improve access to molecular PCR testing in point-of-care settings.
Read more →CODXCo-Diagnostics Announces Second Quarter 2026 Earnings Release Date and Webcast
Co-Diagnostics, Inc. will release its second quarter 2026 financial results on August 13, 2026, after market close. A conference call and webcast will follow at 4:30 p.m. ET, featuring key management including the CEO and CFO. The event will provide insights into the company's financial performance.
Read more →CODX▼ -30.9%on this newsshared move
Co-Diagnostics Joint Venture CoSara Provides Ebola Test Kits for Analytical Studies
Co-Diagnostics, Inc. announced that its joint venture, CoSara, has sent Ebola test kits for evaluation and completed a proof-of-concept study for an extraction-free Ebola test. These developments aim to enhance diagnostic preparedness for viral threats, particularly in response to recent Ebola outbreaks. The company is also working on a pan-Ebola assay to improve detection capabilities.
Read more →CODXCo-Diagnostics Joint Venture CoSara Initiates Clinical Studies in India for Tuberculosis Test on PCR Platform
Co-Diagnostics, Inc. announced that its joint venture, CoSara Diagnostics, has initiated clinical studies for a tuberculosis test using the CoSara PCR Pro instrument in India. This marks a significant step in enhancing access to rapid PCR testing for tuberculosis in a country with a high burden of the disease. The Co-Dx PCR platform aims to provide quick results through a mobile application, although regulatory approvals are still required.
Read more →About Co-Diagnostics, Inc.
Headquarters2401 S FOOTHILL DRIVE, SALT LAKE CITY, UT, 84109
BIOPHARMAWATCH ELITE PLUS
Trade the next CODX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime